Development and validation of risk models and molecular diagnostics to permit personalized management of cancer

E-ISSN： 1097-0142|120|1|11-19

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.1, 2014-01, pp. : 11-19

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Risk-based and diagnostics-linked personalized medicine for cancer

By Srivastava Sudhir Wagner Paul D

Personalized Medicine, Vol. 4, Iss. 1, 2007-02 ,pp. : 33-43

Future Medicine

Access to resources Recommend Favorite

Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 93, Iss. 3, 2013-03 ,pp. : 252-259

John Wiley & Sons Inc

Access to resources Recommend Favorite

Patient‐derived organoid models help define personalized management of gastrointestinal cancer

BRITISH JOURNAL OF SURGERY, Vol. 105, Iss. 2, 2018-01 ,pp. : e48-e60

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cytogenetics and molecular pathology in cancer diagnostics

By Knuutila Sakari

Annals of Medicine, Vol. 36, Iss. 3, 2004-05 ,pp. : 162-171

Informa Healthcare

Access to resources Recommend Favorite

Benefit–risk management in the age of personalized healthcare

By Forstner Michael

Personalized Medicine, Vol. 9, Iss. 5, 2012-07 ,pp. : 507-514

Future Medicine

Access to resources Recommend Favorite